Combined therapy interferon and chemotherapy in chronic myelogenous leukemia

Nouv Rev Fr Hematol (1978). 1989;31(2):171-3.

Abstract

In view of the results achieved by others with interferons and also with low doses of Cytosine-arabinoside, we have treated 24 patients with IFN alpha 2a and Hydroxyurea for induction, with addition of low dose Ara-C during IFN maintenance therapy when the cytogenetic results were deemed insufficient. Complete hematological responses were obtained in 75% of the cases. Cytogenetic responses were noted in 83% of 12 previously untreated (complete or almost complete response in 3) and in 50% of previously treated patients (complete or almost complete response in 3 patients).

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Child
  • Child, Preschool
  • Combined Modality Therapy
  • Cytarabine / administration & dosage
  • Drug Evaluation
  • Humans
  • Hydroxyurea / administration & dosage
  • Interferon Type I / therapeutic use*
  • Interferon alpha-2
  • Interferon-alpha / therapeutic use*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy*
  • Middle Aged
  • Recombinant Proteins
  • Remission Induction

Substances

  • Interferon Type I
  • Interferon alpha-2
  • Interferon-alpha
  • Recombinant Proteins
  • Cytarabine
  • Hydroxyurea